TOTAL PLAY REFINANCES $1,000 MILLION PESOS OF CERTIFICADOS BURSATILES
The issuance represents a vote of confidence from the financial community in the positive prospects of the business, its broad value creation, and the increasing financial strength of Total Play.
The company has the firm intention to continue promoting its strategy that increases operational efficiency, which, together with its strict financial discipline, further strengthens Total Play's profitability and cash generation.
About Total Play
Total Play is a leading Triple Play provider in
Total Play is a Grupo Salinas company (www.gruposalinas.com), a group of dynamic, fast-growing, and technologically advanced companies focused on creating economic value through market innovation and goods and services that improve standards of living; social value to improve community well-being; and environmental value by reducing the negative impact of its business activities. Created by Mexican entrepreneur
Except for historical information, the matters discussed in this press release are concepts about the future that involve risks and uncertainty that may cause actual results to differ materially from those projected. Other risks that may affect Total Play and its subsidiaries are presented in documents sent to the securities authorities.
Investor Relations:
+ 52 (55) 1720 9167 | + 52 (55) 1720 9167 |
Press Relations:
Tel. +52 (55) 1720 1313 ext. 36553
[email protected]
View original content:https://www.prnewswire.com/news-releases/total-play-refinances-1-000-million-pesos-of-certificados-bursatiles-302126659.html
SOURCE Total Play Telecomunicaciones, S.A.P.I. de C.V.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NATIONAL CIVIL RIGHTS TRIAL ATTORNEY JOHN GOMEZ TO ANNOUNCE WHISTLEBLOWER RETALIATION LAWSUIT AGAINST CORONA-NORCO UNIFIED SCHOOL DISTRICT
- Corgi Insurance Launches Golden, a Dedicated Sports and Entertainment Insurance Vertical Built for the $600 Billion Sports Industry
- Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share